Does this statin make you more likely to get diabetes after a kidney transplant?
#2667 The effect of pravastatin on insulin resistance in kidney transplant recipients. A randomized, placebo-controlled cross over trial
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 11 people who got new kidneys a common cholesterol drug called pravastatin for 12 weeks and checked if it made their blood sugar worse.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 547 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 11 people who got new kidneys a common cholesterol drug called pravastatin for 12 weeks and checked if it made their blood sugar worse.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 547 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Related Content
Claims (6)
HMG-CoA reductase inhibition with statins modestly increases the risk of developing type 2 diabetes, particularly in individuals with pre-existing insulin resistance.
Taking pravastatin for 12 weeks didn't make the body better or worse at using insulin to control blood sugar in people who had a kidney transplant and don't have diabetes.
Taking pravastatin for 3 months didn't raise or lower average blood sugar or long-term glucose control in kidney transplant patients without diabetes.
After drinking a sugary solution, pravastatin didn't make blood sugar rise more or less than a placebo in kidney transplant patients without diabetes.
Taking pravastatin for 3 months didn't harm the transplanted kidney's ability to work in patients without diabetes.